MorphoSys AG
FRANKFURT : MOR

February 27, 2012 01:44 ET

MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - Feb 27, 2012) -

MorphoSys AG / MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the signing of a protein engineering agreement with a large bio-pharmaceutical company. The non-exclusive license agreement covers the delivery of multiple Slonomics®-based DNA libraries. The libraries will encode a broad range of protein classes, excluding antibodies, and will be used by its partner for drug discovery. MorphoSys will receive committed annual funding for the delivery of libraries over the three-year lifetime of the agreement and stands to receive milestone and royalty payments on each product emerging from the collaboration.

"This fourth alliance around the Slonomics technology further illustrates the value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Slonomics is a powerful method for making libraries of all types, and this agreement exemplifies the commercial opportunity it creates for us beyond the antibody field."

The Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed. The technology provides a new and flexible approach to generating optimized proteins. MorphoSys acquired Slonomics through Sloning BioTechnology in October 2010.


About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys. Ylanthia® and 100 billion high potentials™ are trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


Media Release: http://hugin.info/130295/R/1588398/498515.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1588398]

Contact Information

  • For more information, please contact:

    MorphoSys AG

    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact